Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study

被引：0
|
作者：
Kim, Tae-Hwan
Yang, Cheongin
Choi, Yong Won
Kwon, Minsuk
Lee, Hyun Woo
Kang, Seok Yun
Ahn, Mi Sun
Choi, Jin-Hyuk
机构：
[1] Ajou Univ, Sch Med, Suwon, South Korea
[2] Ajou Univ, Suwon, Gyeonggi, South Korea
[3] Ajou Univ, Suwon, South Korea
[4] Ajou Univ, Sch Med, Dept Hematol Oncol, Suwon, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20580
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Induction immune checkpoint inhibitors and chemotherapy for patients with stage III non-small cell lung cancer: A real-world experience
    Zheng, Shuohan
    Sun, Ciming
    Zhang, Hao
    Xu, Huimin
    Dong, Baiqiang
    Hou, Zan
    Chen, Ming
    Li, Qiwen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
    Kuusisalo, Saara
    Koivunen, Jussi P.
    Iivanainen, Sanna
    CANCERS, 2022, 14 (09)
  • [23] Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI)
    Iranzo, P.
    Callejo, A.
    Marmolejo, D.
    Assaf, J. D.
    Pardo, N.
    Navarro, A.
    Martinez-Marti, A.
    Cedres, S.
    Diaz Mejia, N. M.
    Carbonell, C.
    Amat, R.
    Frigola, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S767 - S767
  • [24] Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway
    Gartner, Fabian
    Assmus, Jorg
    Flotten, Oystein
    Ramnefjell, Maria Paula
    Aanerud, Marianne
    ACTA ONCOLOGICA, 2022, 61 (07) : 814 - 818
  • [25] Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study
    Jiang, Haohua
    Li, Yujing
    Wang, Yanan
    Zou, Benkun
    Chen, Ya
    Zhang, Yanwei
    Husain, Hatim
    Forest, Fabien
    Qian, Fangfei
    Zhang, Lele
    Zhou, Chao
    Liu, Hongyu
    Wang, Danni
    Zhang, Wei
    Lu, Jun
    Han, Baohui
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07)
  • [26] Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer
    Wan, R.
    Duan, J.
    Wang, Z.
    Lin, L.
    Li, W.
    Jie, W.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
  • [27] A real-world experience of immune checkpoint inhibitors: immunotherapy related adverse events for locally advanced and metastatic non-small cell lung cancer
    Sidon, L.
    Dillon, M.
    Power, D.
    Dubash, S.
    LUNG CANCER, 2020, 139 : S49 - S49
  • [28] Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer
    Youn, Bora
    Trikalinos, Nikolaos A.
    Mor, Vincent
    Wilson, Ira B.
    Dahabreh, Issa J.
    CANCER, 2020, 126 (05) : 978 - 985
  • [29] Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer
    Tang, Monica
    Lee, Chee K.
    Lewis, Craig R.
    Boyer, Michael
    Brown, Bernadette
    Schaffer, Andrea
    Pearson, Sallie-Anne
    Simes, Robert J.
    LUNG CANCER, 2022, 166 : 40 - 48
  • [30] Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye
    Yavuz, Melike Yuksel
    Karapinar, Filiz
    Anar, Ceyda
    Ok, Mehdi
    Erturk, Sema
    Gayaf, Mine
    Ucsular, Fatma Demirci
    Polat, Guelru
    MEDICAL SCIENCE MONITOR, 2025, 31
12345